论文部分内容阅读
[目的]运用血清蛋白质组分析技术(SERPA)鉴定非小细胞肺癌(NSCLC)的肿瘤相关抗原。[方法]提取NSCLC肿瘤组织的胞浆蛋白,经二维凝胶电泳分离后转膜,用患者或健康对照血清为一抗进行免疫印迹分析,比较免疫印迹的结果,在未转膜的参比凝胶上找到差异蛋白点,进行MALDI-TOF鉴定;用免疫组化方法验证NSCLC组织中候选抗原的表达。[结果]本研究共鉴定4个候选蛋白。CCT5在肺鳞癌和肺腺癌组织中表达明显升高,且主要定位于癌细胞浆,胞核未检测到表达。[结论]CCT5可能是NSCLC的肿瘤相关抗原。
[Objective] To identify tumor-associated antigens of non-small cell lung cancer (NSCLC) by serum proteomic analysis (SERPA). [Method] The cytoplasmic proteins of NSCLC tumor tissues were extracted, separated by two-dimensional gel electrophoresis and then transferred to the membrane. Western blot analysis was performed with the patients or healthy control serum as the primary antibody. The results of immunoblotting were compared with those of the untransfected membrane The differentially expressed protein spots were identified on the gel and identified by MALDI-TOF. The expression of candidate antigens in NSCLC tissues was verified by immunohistochemistry. [Result] Four candidate proteins were identified in this study. The expression of CCT5 in squamous cell carcinoma and lung adenocarcinoma tissues was significantly increased, and mainly located in the cytoplasm of cancer cells, but no expression was detected in the nucleus. [Conclusion] CCT5 may be tumor associated antigen of NSCLC.